Effect of tamsulosin on ejaculatory function in BPH/LUTS  

作　　者：Sang Hoon Song Hwancheol Son Kwang Taek Kim Sae Woong Kim Du Geon Moon Ki Hak Moon Kwangsung Park Jong Kwan Park Sung-Won Lee Jae Seog Hyun Nam Cheol Park 

机构地区：[1]Jeungpyung Health Center, Jeungpyung-gun, Chungbuk, 368-900, Korea [2]Department of Urology, Seoul Metropolitan Boramae Hospital, Seoul, 156-707, Korea [3]Aerospace Medical Center, Cheongwon, Chungbuk, 363-840, Korea [4]Catholic University of Korea College of Medicine, Seoul, 137-701, Korea [5]Korea University College of Medicine, Seoul, 152-703, Korea [6]Department of Urology, Yeungnam University College of Medicine, Daegu, 705-717, Korea [7]Department of Urology, Chonnam National University Medical School, Gwangju, 501-757, Korea [8]Department of Urology, Medical School and Institute for Medical Sciences, Chonbuk National University, Chonbuk, 561-712, Korea [9]Research Institute of Clinical Medicine and CTC for Medical Device of Chonbuk National University Hospital, Chonbuk, 561-712, Korea [10]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, Korea [11]Gyeongsang National University, Gyeongnam, 660-702, Korea [12]pusan National University College of Medicine, Pusan, 602-739, Korea

出　　处：《Asian Journal of Andrology》2011年第6期846-850,共5页亚洲男性学杂志（英文版）

摘　　要：This study was undertaken to determine the impact on ejaculatory function of tamsulosin （0.2 mg） given once daily （OD） for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score （IPSS） ≥ 8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire （MSHQ）, and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2 mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains （EFD, EjFD, SDA and ADD） or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction （EjD） was 13.4%. Incidences of the seven different types of EjD （decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation） were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for I PSS responders than for non-responders （26.09 vs. 24.06, P=0.03）. An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.This study was undertaken to determine the impact on ejaculatory function of tamsulosin （0.2 mg） given once daily （OD） for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score （IPSS） ≥ 8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire （MSHQ）, and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2 mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains （EFD, EjFD, SDA and ADD） or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction （EjD） was 13.4%. Incidences of the seven different types of EjD （decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation） were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for I PSS responders than for non-responders （26.09 vs. 24.06, P=0.03）. An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.

关 键 词：alpha-1 adrenergic receptors benign prostatic hyperplasia EJACULATION lower urinary tract symptom Male Sexual HealthQuestionnaire prostatic hyperplasia TAMSULOSIN 

分 类 号：O212.1[理学—概率论与数理统计] S826.3[理学—数学]